A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer

The standard treatment for prostate cancer (PCa) is androgen deprivation therapy (ADT) that blocks transcriptional activity of androgen receptor (AR). However, ADT invariably leads to the development of castration-resistant PCa (CRPC) with restored activity of AR. CRPC can be further treated with CY...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Dong, Gao, Shuai, Valencia, Kevin, Owiredu, Jude, Han, Wanting, de Waal, Eric, Macoska, Jill A, Cai, Changmeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351670/
https://www.ncbi.nlm.nih.gov/pubmed/28036278
http://dx.doi.org/10.18632/oncotarget.14296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351670/
https://www.ncbi.nlm.nih.gov/pubmed/28036278
http://dx.doi.org/10.18632/oncotarget.14296

Ejemplares similares